- Home
- JAZZ vs MGM Comparison
JAZZ vs MGM Comparison
Compare JAZZ & MGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- MGM
- Stock Information
- Founded
- JAZZ 2003
- MGM 1986
- Country
- JAZZ Ireland
- MGM United States
- Employees
- JAZZ N/A
- MGM N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- MGM Hotels/Resorts
- Sector
- JAZZ Health Care
- MGM Consumer Discretionary
- Exchange
- JAZZ Nasdaq
- MGM Nasdaq
- Market Cap
- JAZZ 8.4B
- MGM 9.3B
- IPO Year
- JAZZ 2007
- MGM N/A
- Fundamental
- Price
- JAZZ $122.92
- MGM $30.37
- Analyst Decision
- JAZZ Strong Buy
- MGM Strong Buy
- Analyst Count
- JAZZ 13
- MGM 16
- Target Price
- JAZZ $187.15
- MGM $51.06
- AVG Volume (30 Days)
- JAZZ 1.3M
- MGM 5.7M
- Earning Date
- JAZZ 04-30-2025
- MGM 04-30-2025
- Dividend Yield
- JAZZ N/A
- MGM N/A
- EPS Growth
- JAZZ 41.75
- MGM N/A
- EPS
- JAZZ 8.65
- MGM 2.40
- Revenue
- JAZZ $4,068,950,000.00
- MGM $17,240,545,000.00
- Revenue This Year
- JAZZ $7.30
- MGM $1.44
- Revenue Next Year
- JAZZ $4.01
- MGM $1.79
- P/E Ratio
- JAZZ $14.21
- MGM $12.65
- Revenue Growth
- JAZZ 6.12
- MGM 6.66
- 52 Week Low
- JAZZ $99.06
- MGM $29.99
- 52 Week High
- JAZZ $148.06
- MGM $48.25
- Technical
- Relative Strength Index (RSI)
- JAZZ 32.69
- MGM 37.28
- Support Level
- JAZZ $137.74
- MGM $31.16
- Resistance Level
- JAZZ $142.64
- MGM $32.41
- Average True Range (ATR)
- JAZZ 3.87
- MGM 1.00
- MACD
- JAZZ -2.12
- MGM -0.00
- Stochastic Oscillator
- JAZZ 0.45
- MGM 11.43
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About MGM MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.